Eli Lilly's Kisunla is the second treatment available in the U.S. that has been shown in trials to modestly slow a decline in memory.
U.S. officials have approved an Alzheimer's drug that can modestly slow the disease and a decline in memory, providing a new option to patients suffering from the memory-destroying ailment. The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s.
Louis, told The Associated Press. "It’s been difficult as a dementia specialist — I diagnose my patients with Alzheimer’s and then every year I see them get worse and they progress until they die."The delay seen with both drugs amounts to a matter of months — about seven months, in the case of Lilly’s drug. Patients and their families will have to weigh that benefit against the downsides, including regular IV infusions and potentially dangerous side effects like brain swelling.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »
FDA advisors recommend Eli Lilly Alzheimer’s drug that slows diseaseEli Lilly's new Alzheimer's drug, donanemab, received approval from an advisory panel for the FDA. The full agency is expected to approve the drug by spring.
Read more »
Alzheimer’s drug from Eli Lilly wins backing of FDA committeeAn advisory committee to the Food and Drug Administration found the drug was safe and effective at slowing the progression of the disease, setting the stage for the agency to approve it.
Read more »
FDA approves new Alzheimer's treatment, donanemab from Eli LillyFDA approval of the new Alzheimer's treatment, which will be branded as Kisunla, follows years of setbacks.
Read more »